Author
Listed:
- Jason Gordon
(Health Economics and Outcomes Research Limited)
- Oliver Darlington
(Health Economics and Outcomes Research Limited)
- Phil McEwan
(Health Economics and Outcomes Research Limited)
- Matthew Lumley
(Pfizer)
- Amer Taie
(Pfizer)
- Meagen Hicks
(Pfizer)
- Claudie Charbonneau
(Pfizer)
- Angela Blake
(Pfizer)
- Neil Hawkins
(University of Glasgow)
- Simon Goldenberg
(Guy’s and St Thomas’ NHS Foundation Trust)
- Jonathan Otter
(Imperial College London)
- Mark Wilcox
(University of Leeds)
Abstract
Objectives Antimicrobial resistance (AMR) represents a significant threat to patient and population health. The study aim was to develop and validate a model of AMR that defines and quantifies the value of new antibiotics. Methods A dynamic disease transmission and cost-effectiveness model of AMR consisting of three components (disease transmission, treatment pathway and optimisation) was developed to evaluate the health economic value of new antibiotics. The model is based on the relationship between AMR, antimicrobial availability and consumption. Model analysis explored the impact of different antibiotic treatment strategies on the development of AMR, patient and population estimates of health benefit, across three common treatment indications and pathogens in the UK. Results Population-level resistance to existing antimicrobials was estimated to increase from 10.3 to 16.1% over 10 years based on current antibiotic availability and consumption. In comparison, the diversified use of a new antibiotic was associated with significant reduction in AMR (12.8% vs. 16.1%) and quality-adjusted life year (QALY) gains at a patient (7.7–10.3, dependent on antimicrobial efficacy) and population level (3657–8197, dependent on antimicrobial efficacy and the prevalence of AMR). Validation across several real-world data sources showed that the model output does not tend to systematically under- or over-estimate observed data. Conclusions The development of new antibiotics and the appropriate use of existing antibiotics are key to addressing the threat of AMR. This study presents a validated model that quantifies the value of new antibiotics through clinical and economic outcomes of relevance, and accounts for disease transmission of infection and development of AMR. In this context, the model may be a useful tool that could contribute to the decision-making process alongside other potential models and expert advice.
Suggested Citation
Jason Gordon & Oliver Darlington & Phil McEwan & Matthew Lumley & Amer Taie & Meagen Hicks & Claudie Charbonneau & Angela Blake & Neil Hawkins & Simon Goldenberg & Jonathan Otter & Mark Wilcox, 2020.
"Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model,"
PharmacoEconomics, Springer, vol. 38(8), pages 857-869, August.
Handle:
RePEc:spr:pharme:v:38:y:2020:i:8:d:10.1007_s40273-020-00906-6
DOI: 10.1007/s40273-020-00906-6
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:38:y:2020:i:8:d:10.1007_s40273-020-00906-6. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.